Brief: Bioporto Q3 EBIT Loss Widens To DKK 24 Million

BioPorto A/S

21/11/2019 07:53

Nov 21 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * REG-BIOPORTO ANNOUNCES Q3 2019 REPORT
    * REG-BIOPORTO ANNOUNCES Q3 2019 REPORT
    * GUIDANCE FOR 2019 REVISED
    * CHANGED ITS FINANCIAL GUIDANCE FOR 2019 TO APPROXIMATELY
DKK 29
MILLION IN REVENUE AND EBIT LOSS OF APPROXIMATELY DKK 70
MILLION.
    * REVENUE IN Q3 OF 2019 GREW BY 24% TO DKK 6.6 MILLION
COMPARED TO
DKK 5.4 MILLION LAST YEAR
    * Q3 EBIT LOSS DKK 24 MILLION VERSUS LOSS DKK 11.5 MILLION
YEAR
AGO
    * WILL BUILD A FOLLOW-ON DATASET DESIGNED TO DEMONSTRATE
NGAL'S
UTILITY NOT ONLY TO CLINICIANS, BUT ALSO TO FDA
    * EXPECTS TO SUBMIT A REVISED AND SUPPLEMENTED APPLICATION
IN Q2
2020.
    * ON TOP OF A GOOD Q3 WITH SATISFYING GROWTH IN REVENUE AND
EXECUTING ACCORDING TO PLAN, WE UNFORTUNATELY HAD TO ANNOUNCE A
DELAY IN OUR US PEDIATRIC APPLICATION PROCESS FOR NGAL TEST
    * US REVENUES FROM NGAL GREW BY 29% IN QUARTER COMPARED TO
SAME
QUARTER LAST YEAR
    * SECONDLY, SALES OF ANTIBODIES REMAINED POSITIVELY AFFECTED
BY
HIGHER BULK ORDERS

Source text for Eikon:  ID:nGNE68kZsN 
Further company coverage:  BIOPOR.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))